Intravenous Ascorbic Acid (IVAA) for COVID-19 Supportive Treatment in Hospitalized COVID-19 Patients (Based on use in China and US settings)

Subscribe to access this work and thousands more
Abstract: 
Intravenous ascorbic acid (IVAA) is a well-known intervention in medicine, which currently is rarely used 
in US hospitals. Due to the unusual and extreme clinical demands of hospitalized COVID-19 patients,
IVAA has been implemented in Chinese hospitals, and data published by the “Expert Group on Clinical 
Treatment of New Corona Virus Disease in Shanghai” (direct translation) details the use of IVAA as safe 
and effective adjunctive care of hospitalized COVID-19 patients. In the IVAA treated group, there was no 
mortality, no reported side effects, and shorter hospital stays universally. In addition, the Shanghai 
Expert Group recommends IVAA use in extremely critical settings within COVID-19 patients. IVAA, as an 
intervention, is relatively inexpensive and simple for both pharmacy and nursing staff use. The primary 
author has also used IVAA in the US under a NIH funded human trial and has extensive subject matter 
knowledge and expertise.

Subscribe to access this work and thousands more